New cancer clinical trial: Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Published on: October 26, 2018 at 12:00PM
Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Oxaliplatin;   Drug: L-Leucovorin;   Drug: 5-fluorouracil;   Drug: Atezolizumab
Sponsors:   Gruppo Oncologico del Nord-Ovest;   Roche Pharma AG
Not yet recruiting
https://ift.tt/2Sit9Xw